Drug Profile
Ibodutant - Menarini Pharmaceuticals
Alternative Names: MEN-15596Latest Information Update: 02 Feb 2018
Price :
$50
*
At a glance
- Originator Menarini
- Class Small molecules; Thiophenes
- Mechanism of Action Neurokinin 2 receptor antagonists; Tachykinin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Irritable bowel syndrome
Most Recent Events
- 02 Feb 2018 Discontinued - Phase-II for Irritable bowel syndrome in Ukraine (PO)
- 02 Feb 2018 Discontinued - Phase-III for Irritable bowel syndrome in Hungary, Latvia, Sweden, Spain, Slovakia, Germany, United Kingdom, Poland, Singapore, Bulgaria, France, Italy, USA, Russia, Romania, Czech Republic (PO)
- 31 May 2016 Menarini terminates its phase III trial for Irritable bowel syndrome in USA, Hungary, Latvia, Sweden, Slovakia, Germany and United Kingdom prior to May 2016(NCT02120027) (PO)